NCT05181683View on ClinicalTrials.gov

COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 7, 2022

Primary Completion Date

June 3, 2022

Study Completion Date

June 3, 2022

Conditions

HealthyChronic Stable Illness

Interventions

DRUG

Casirivimab+Imdevimab

Randomized 1:1 for intravenous (IV) or subcutaneous (SC) administration

Trial Locations (2)

32789

Regeneron StudySite, Winter Park

33186

Regeneron Study Site, Miami

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT05181683 - COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers | Biotech Hunter | Biotech Hunter